Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. (Q40795101)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

0 references

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

P S Belperio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

T A Shahoumian

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

T P Loomis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

L A Mole

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

English

0 references

publication date

26 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

559-573

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

18 February 2020

cites work

1 reference

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting

21 January 2018

1 reference

Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET.

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

Clinical Case Registries: simultaneous local and national disease registries for population quality management

21 January 2018

1 reference

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review

21 January 2018

1 reference

21 January 2018

1 reference

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection

21 January 2018

1 reference

Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

Review article: genetic factors that modify the outcome of viral hepatitis

21 January 2018

1 reference

The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.13300

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26113432%20AND%20SRC:MED&resulttype=core&format=json